Recent news and posts
New Nominative lists with reimbursable brand-specific devices for vascular surgery introduced in Belgium
On April 22, 2021, the List of reimbursable implants and invasive medical devices, maintained by the National Institute for Health and Disability Insurance (INAMI), was updated with the corresponding Nominative lists of brand-specific devices. Two new Nominative lists with reimbursable devices used for peripheral vascular interventions were introduced.
Newly-introduced Nominative list 360, “Drug-eluting stent (femoropopliteal arteries),” includes the following devices:
- 360030000114 Zilver PTX Drug-Eluting Peripheral Stent by Cook;
- 360030000213 Eluvia - Drug-Eluting Vascular Stent System by Boston Scientific Benelux.
The reimbursement tariff for these devices is €1,485.70.
Newly-introduced Nominative list 361 “Drug-eluting balloon (femoropopliteal arteries)” includes the following devices:
- 361050000149 IN.PACT Pacific by Medtronic;
- 361050000248 IN.PACT Admiral by Medtronic;
- 361050000347 and 361050000446 Stellarex drug-coated balloon by SPECTRANETICS;
- 361050000545 and 361050000644 Stellarex drug-coated balloon by Medicor;
- 361050000743 Ranger DCB OTW by Boston Scientific Benelux;
- 361050000842 Ranger SL DCB OTW by Boston Scientific Benelux;
- 361050000941 Luminor 18 paclitaxel-eluting PTA balloon by iVascular;
- 361050001040 Sequent Please OTW by B Braun;
- 361050001139 Luminor 35 paclitaxel-eluting PTA balloon by iVascular.
The reimbursement tariff for these devices is €1,485.70.
The Nominative lists can be seen here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).